Implementing Minor Changes is Hard to Do Under Variations Regulation
This article was originally published in The Gold Sheet
European generic drug makers say that it is difficult to implement Type IA changes under the variations regulation because of all the paperwork involved in submitting these changes to competent authorities. A 26 percent fee hike in filing variations is also making it more costly and difficult for manufacturers to justify making changes.
You may also be interested in...
Minor Changes Still Burdensome to Report Under Revised Variations Regulation, European Industry and Competent Authorities Complain
Latest EU variations rewrite leaves both industry and regulators with concerns. Minor changes would still be difficult to implement and pre-notification requirements are seen as unworkable. A plan to subject all biologics changes to prior approval draws ire of biotech sector
While COVID-19 continues to wreak havoc on FDA's ability to perform onsite preapproval inspections, new guidance offers some clarity, but the news isn't great for ANDA holders.
The WHO proposes to revise 2011 guidance on technology transfers to ease the hand-off of COVID-19 drugs and vaccines from research and development facilities to commercial sites.